Rebecca Araujo

DocwireNews

<div id="meta" class="style-scope ytd-watch-flexy">
<div id="meta-contents" class="style-scope ytd-watch-flexy">
<div id="container" class="style-scope ytd-video-secondary-info-renderer">
<div id="content" class="style-scope ytd-expander">
<p>Results from the ANDROMEDA trial showed that Darzalex Faspro (daratumumab and hyaluronidase human-fihj) was an effective treatment for patients with light-chain (AL) amyloidosis.</p>
<p>DocWire News spoke with study co-author Raymond Comenzo, MD, Director of Transfusion Medicine and Professor at the Tufts University School of Medicine about these findings, which were featured at the American Society of Hematology (ASH) 2020 virtual annual conference (<a href="https://ash.confex.com/ash/2020/webprogram/Paper137582.html" target="_blank" rel="noopener noreferrer">abstract #552</a>).</p>
<p><strong>DocWire News:</strong> Today, we&rsquo;re talking about data that will be presented at the upcoming ASH 2020 annual conference regarding the phase III ANDROMEDA study, illustrating the promise of Darzalex Faspro as a potential treatment for patients with <a href="https://www.docwirenews.com/condition-center/al-amyloidosis-knowledge-hub/al-amyloidosis-picks/researchers-assess-utility-of-response-criteria-for-al-amyloidosis-therapy/" target="_blank" rel="noopener noreferrer">light-chain amyloidosis</a>. Dr. Comenzo, can you just walk us through some of the highlights of this study?</p>
</div>
<div class="style-scope ytd-comments-header-renderer"><strong>Raymond Comenzo, MD:</strong> I think it&rsquo;s very important to start with the fact that there are no approved drugs to treat patients with light-chain amyloidosis. This is a disease in which <a href="https://www.docwirenews.com/condition-center/al-amyloidosis-knowledge-hub/high-incidence-of-arterial-thromboembolic-events-in-patients-with-cardiac-amyloidosis/" target="_blank" rel="noopener noreferrer">plasma cells</a> in the bone marrow that are clonal, make a protein that deposits in the body&rsquo;s organs, notably in the heart and kidneys, and without elimination of these plasma cells in the bone marrow, patients to die in a matter of months to a few years.</div>
<p>The use of immunotherapy in the form of anti-CD38 monoclonal antibody therapy, which that tumor map provides, is an extremely important advance in the treatment of these patients. In the clinical trial ANDROMEDA, a standard approach with chemotherapy using bortezomib, cyclophosphamide, and dexamethazone was compared with that standard approach, plus daratumumab. A critical aspect of daratumumab in this trial was that it was a 15 milliliter infusion under the skin, lasting maybe four or five minutes for the infusion itself, but it did not require intravenous fluids. Patients with light-chain amyloid and <a href="https://www.docwirenews.com/condition-center/al-amyloidosis-knowledge-hub/al-amyloidosis-picks/effusion-linked-to-ventricular-function-and-prognosis-in-cardiac-amyloidosis/" target="_blank" rel="noopener noreferrer">heart involvement</a>, they get into trouble if too much intravenous fluid is administered to them.</p>
<p>The trial is completed. The results will be presented at ASH following up on the initial presentations at the European Hematology Association meeting in June, and the results showed that the combination of daratumumab with chemotherapy was far better than chemotherapy alone in achieving very prompt elimination of the plasma cells in the bone marrow in over 50% of patients, allowing their organs to improve, and hopefully allowing them to live longer.</p>
<p><strong>DocWire News:</strong> What are some hopeful clinical implications of these results?</p>
<p><strong>Dr. Comenzo:</strong> We&rsquo;re at a time in <a href="https://www.docwirenews.com/condition-center/al-amyloidosis-knowledge-hub/daratumumab-is-safe-and-effective-for-relapsed-refractory-al-amyloidosis/" target="_blank" rel="noopener noreferrer">amyloid therapies</a> when the existence of effective treatments will accelerate the diagnosis of the disease itself. It provides an incentive for physicians to make the diagnosis because they can then offer therapy. This applies to all the different types of amyloid that can cause <a href="https://www.docwirenews.com/condition-center/al-amyloidosis-knowledge-hub/reasonable-short-term-outcomes-for-heart-transplant-in-patients-with-cardiac-amyloidosis/" target="_blank" rel="noopener noreferrer">heart</a> involvement. There are three major types, two of them related to a molecule called transthyretin, and one related to light chains, the AL type which we&rsquo;re speaking about today. This will change the timing of the diagnosis and the timing of the beginning of therapy with an extremely effective combination. Should it be approved by the FDA, which we all anticipate, this will enable patients to get better faster, and will enable more patients to survive with AL amyloidosis.</p>
<p><strong>DocWire News:</strong> What&rsquo;s next for you and your research team on this project or going forward?</p>
<p><strong>Dr. Comenzo:</strong> Well, there are potential combinations of monoclonal antibodies, as well as monoclonal antibodies that are linked to both other monoclonals that will bring immune cells closer to the culprit plasma cells, and also linked to drugs. So I anticipate that there will be many significant phase II studies using combinations of monoclonal antibodies, and also that some of the newer medicines that have been developed for multiple myeloma may indeed be relevant to patients with light chain amyloid. So having an effective initial therapy means that patients will survive longer, and if and when they relapse, hopefully we&rsquo;ll have more effective therapies available to them at that time.</p>
<blockquote class="twitter-tweet">
<p dir="ltr" lang="en">My favorite topic <a href="https://twitter.com/hashtag/amyloidosis?src=hash&amp;ref_src=twsrc%5Etfw">#amyloidosis</a>: Update on Andromeda Dara-CyBorD vs CyBorD by Ray Comenzo<br>
&#10145;&#65039;Dara-CyBorD results in longer PFS<br>
&#10145;&#65039;Dara-CyBorD significantly delays organ deterioration<br>
Dara-CyBorD is clearly the new SOC in AL! But is Dara maintenance also the new SOC? <a href="https://twitter.com/hashtag/ASH20?src=hash&amp;ref_src=twsrc%5Etfw">#ASH20</a> <a href="https://twitter.com/hashtag/ASH20SL?src=hash&amp;ref_src=twsrc%5Etfw">#ASH20SL</a> <a href="https://t.co/tXCIFIN7yu">pic.twitter.com/tXCIFIN7yu</a></p>
<p>&mdash; Dr. Suzanne Lentzsch (@SLentzsch) <a href="https://twitter.com/SLentzsch/status/1335996713476165636?ref_src=twsrc%5Etfw">December 7, 2020</a></p>
</blockquote>
<p><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></p>
</div>
</div>
</div>


Jordana Jampel

Modernization and the Rising Burden of IBD: New Insights From a Global Study

Gastroenterology

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Latest News

ASH 2020: Raymond Comenzo, MD, Discusses Darzalex Faspro for AL Amyloidosis

ASH Annual Meeting 2020

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe